EMA Tackles Hurdles To Using Single-Arm Trial Data For Pivotal Evidence In Filings

The European Medicines Agency has highlighted issues for drug developers to consider when seeking to submit clinical data from SATs as the pivotal evidence in their marketing authorization applications instead of randomized controlled trial data.